Ravi Bhatia

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

Hagop M. Kantarjian, Francis J. Giles, Norbert Gattermann et al. · Blood · 2007 · 742 citations · Full text

PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia

Zhaohui Gu, Michelle L. Churchman, Kathryn G. Roberts et al. · Nature Genetics · 2019 · 578 citations · Full text

Hematological Malignancy, Mixed-phenotype Acute Leukemia, Pax5-driven Subtypes +4

miR-328 Functions as an RNA Decoy to Modulate hnRNP E2 Regulation of mRNA Translation in Leukemic Blasts

Anna M. Eiring, Jason G. Harb, Paolo Neviani et al. · Cell · 2010 · 561 citations · Full text

Genetics, Mrna Translation, Mir-328 Functions +9

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment

Ravi Bhatia, Melissa Holtz, Ning Niu et al. · Blood · 2003 · 540 citations · Full text

Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma

Christopher J. Gibson, R. Coleman Lindsley, Vatche Tchekmedyian et al. · Journal of Clinical Oncology · 2017 · 455 citations · Full text